1Wk·

Dispute is resolved

Wegovy maker Novo Nordisk$NOVO B (-0.05%) plans to sell its weight-loss drugs on Hims & Hers Health $HIMS (-2.56%) platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.

Novo and Hims plan to announce a new partnership as soon as Monday.

$HIMS (-2.56%) up 40% in after hours!

9 Comments

Arno D.@RealArnoDuebel

1Wk

40% for HIMS is nice but what about the $NOVO B shareholder 😅 we could need some recovery as well please

•

Ssg@Sssggg

1Wk

LETS GO

•

TD@Routine123

1Wk

What a comedy this is😂

•

Balance seeker@Balance_seeker

1Wk

I was waiting for this! It was the only reason for staying in $hims

••

Luuk@Luukratief

1Wk

@Balance_seeker why? Its just a bad narrative about the company, thats overblown on the stockprice. The company starts now. No more glp1 bs and narrative, but the real company

••

Balance seeker@Balance_seeker

1Wk

@Luukratief at least is not finned to bankruptcy for infringement of patents like the FDA noticed. The agreement is the only escape from that situation.

••

Luuk@Luukratief

1Wk

@Balance_seeker nope. Thats just fud. They would have always settled, because it is not in novos interest to go through 5 years of court for this, appeal and everything. Its also a lot of uncertainty for them. Hardly any cases make it that far.

••

Balance seeker@Balance_seeker

1Wk

@Balance_seeker just the patents infringement accusations were enough damaging, you can see it on stock prices. The main reason is that GPL1 molecules will be now on the forbidden list to replicate by the FDA and selling generic GPL1 won't be a business model anyone.

••

DAVCAREMMA@DAVCAREMMA

1Wk

The two company's need good news . Nice deal

•